SABCS 2020 – Wrap-Up

A phase 2 trial of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive metastatic breast cancer show high rates of positive results in patients who have been heavily pretreated. These results are preliminary and encouraging. Read More ›

Breast cancer and its treatment impacts sexual health, which is an important topic for patients and clinicians to be able to address throughout the treatment process. Read More ›

The DESTINY-Breast05 trial will help researchers understand the potential benefit of Enhertu (trastuzumab deruxtecan), a powerful potential treatment of patients with breast cancer with residual invasive disease after receiving chemotherapy. Read More ›

Panelists discuss the challenges of the pandemic and its impact on the risk for pandemic-related disruptions in cancer care, breast cancer diagnosis, timing and choice of treatment, and mental health. Read More ›

Minority women need timely, high-quality access to care, as delays in diagnosis and treatment may be fatal. Patients and clinicians need to work together to overcome obstacles, so they can gain access to the best screening, genetic testing, and treatments through clinical trials. Read More ›

In patients with HER2-expressing metastatic breast cancer, Enhertu (trastuzumab deruxtecan) plus Opdivo (nivolumab) demonstrated antitumor activity consistent with previous studies of Enhertu and had an acceptable safety profile in this short-term analysis. Read More ›

For patients with breast cancer, adhering to a diabetes risk reduction diet improved survival when compared with patients who did not follow this diet. Read More ›

To reduce depressive symptoms, behavioral intervention techniques of mindfulness mediation and survivorship education are helpful, according to results from a recent randomized, controlled clinical trial. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares how the San Antonio Breast Cancer Symposium contributes to better care for patients with breast cancer. Read More ›

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer. Read More ›

Page 1 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications